Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 59 entries
Sorted by: Best Match Show Resources per page
Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis.

Mediators of inflammation

Mösges R, Spaeth J, Klimek L.
PMID: 18475683
Mediators Inflamm. 1995;4(7):S11-5. doi: 10.1155/S0962935195000780.

Levocabastine and azelastine are currently the only antihistamines available as nasal sprays for the topical therapy of seasonal allergic rhinitis. The present study was undertaken to compare the onset of action, efficacy and tolerability of these two agents in...

Cite
Mösges R, Spaeth J, Klimek L. Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis. Mediators Inflamm. 1995;4(7):S11-5doi: 10.1155/S0962935195000780.
Mösges, R., Spaeth, J., & Klimek, L. (1995). Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis. Mediators of inflammation, 4(7), S11-5. https://doi.org/10.1155/S0962935195000780
Mösges, R, et al. "Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis." Mediators of inflammation vol. 4,7 (1995): S11-5. doi: https://doi.org/10.1155/S0962935195000780
Mösges R, Spaeth J, Klimek L. Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis. Mediators Inflamm. 1995;4(7):S11-5. doi: 10.1155/S0962935195000780. PMID: 18475683; PMCID: PMC2365678.
Copy Download .nbib Format: NLM
Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies.

Clinical ophthalmology (Auckland, N.Z.)

Epstein AB, Van Hoven PT, Kaufman A, Carr WW.
PMID: 19668586
Clin Ophthalmol. 2009;3:329-36. doi: 10.2147/opth.s5223. Epub 2009 Jun 02.

PURPOSE: Results from 2 patient-reported outcome studies of allergic conjunctivitis sufferers who used olopatadine 0.2% and azelastine 0.05% are analyzed.METHODS: The PACE (Pataday Allergic Conjunctivitis Evaluation) multi-center, prospective, open-label study examined patient perceptions of olopatadine 0.2% once daily (qd)...

Cite
Epstein AB, Van Hoven PT, Kaufman A, et al. Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clin Ophthalmol. 2009;3:329-36doi: 10.2147/opth.s5223.
Epstein, A. B., Van Hoven, P. T., Kaufman, A., & Carr, W. W. (2009). Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clinical ophthalmology (Auckland, N.Z.), 3329-36. https://doi.org/10.2147/opth.s5223
Epstein, Arthur B, et al. "Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies." Clinical ophthalmology (Auckland, N.Z.) vol. 3 (2009): 329-36. doi: https://doi.org/10.2147/opth.s5223
Epstein AB, Van Hoven PT, Kaufman A, Carr WW. Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clin Ophthalmol. 2009;3:329-36. doi: 10.2147/opth.s5223. Epub 2009 Jun 02. PMID: 19668586; PMCID: PMC2709004.
Copy Download .nbib Format: NLM
Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis.

Expert review of clinical immunology

Horak F, Zieglmayer UP.
PMID: 20477689
Expert Rev Clin Immunol. 2009 Nov;5(6):659-69. doi: 10.1586/eci.09.38.

Rhinitis affects millions of people around the world, places a huge burden on the economy and reduces patients' health-related quality of life. Azelastine nasal spray is a second-generation antihistamine, indicated for the treatment of allergic and nonallergic rhinitis in...

Cite
Horak F, Zieglmayer UP. Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis. Expert Rev Clin Immunol. 2009;5(6):659-69doi: 10.1586/eci.09.38.
Horak, F., & Zieglmayer, U. P. (2009). Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis. Expert review of clinical immunology, 5(6), 659-69. https://doi.org/10.1586/eci.09.38
Horak, Friedrich, and Zieglmayer, Ursula Petra. "Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis." Expert review of clinical immunology vol. 5,6 (2009): 659-69. doi: https://doi.org/10.1586/eci.09.38
Horak F, Zieglmayer UP. Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis. Expert Rev Clin Immunol. 2009 Nov;5(6):659-69. doi: 10.1586/eci.09.38. PMID: 20477689.
Copy Download .nbib Format: NLM
Management of allergic rhinitis.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Sausen VO, Marks KE, Sausen KP, Self TH.
PMID: 23118635
J Pediatr Pharmacol Ther. 2005 Jul;10(3):159-73. doi: 10.5863/1551-6776-10.3.159.

Allergic rhinitis is the most common chronic childhood disease. Reduced quality of life is frequently caused by this IgE-mediated disease, including sleep disturbance with subsequent decreased school performance. Asthma and exercise-induced bronchospasm are commonly seen concurrently with allergic rhinitis,...

Cite
Sausen VO, Marks KE, Sausen KP, et al. Management of allergic rhinitis. J Pediatr Pharmacol Ther. 2005;10(3):159-73doi: 10.5863/1551-6776-10.3.159.
Sausen, V. O., Marks, K. E., Sausen, K. P., & Self, T. H. (2005). Management of allergic rhinitis. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 10(3), 159-73. https://doi.org/10.5863/1551-6776-10.3.159
Sausen, Verra O, et al. "Management of allergic rhinitis." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 10,3 (2005): 159-73. doi: https://doi.org/10.5863/1551-6776-10.3.159
Sausen VO, Marks KE, Sausen KP, Self TH. Management of allergic rhinitis. J Pediatr Pharmacol Ther. 2005 Jul;10(3):159-73. doi: 10.5863/1551-6776-10.3.159. PMID: 23118635; PMCID: PMC3468067.
Copy Download .nbib Format: NLM
A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

Ellis AK, Zhu Y, Steacy LM, Walker T, Day JH.
PMID: 23635091
Allergy Asthma Clin Immunol. 2013 May 01;9(1):16. doi: 10.1186/1710-1492-9-16. eCollection 2013.

BACKGROUND: Azelastine has been shown to be effective against seasonal allergic rhinitis (SAR). The Environmental Exposure Unit (EEU) is a validated model of experimental SAR. The objective of this double-blind, four-way crossover study was to evaluate the onset of...

Cite
Ellis AK, Zhu Y, Steacy LM, et al. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol. 2013;9(1):16doi: 10.1186/1710-1492-9-16.
Ellis, A. K., Zhu, Y., Steacy, L. M., Walker, T., & Day, J. H. (2013). A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 9(1), 16. https://doi.org/10.1186/1710-1492-9-16
Ellis, Anne K, et al. "A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 9,1 (2013): 16. doi: https://doi.org/10.1186/1710-1492-9-16
Ellis AK, Zhu Y, Steacy LM, Walker T, Day JH. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy Asthma Clin Immunol. 2013 May 01;9(1):16. doi: 10.1186/1710-1492-9-16. eCollection 2013. PMID: 23635091; PMCID: PMC3655060.
Copy Download .nbib Format: NLM
The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

Bjermer L, Westman M, Holmström M, Wickman MC.
PMID: 31015846
Allergy Asthma Clin Immunol. 2019 Apr 16;15:24. doi: 10.1186/s13223-018-0314-1. eCollection 2019.

Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or...

Cite
Bjermer L, Westman M, Holmström M, et al. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy Asthma Clin Immunol. 2019;15:24doi: 10.1186/s13223-018-0314-1.
Bjermer, L., Westman, M., Holmström, M., & Wickman, M. C. (2019). The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 1524. https://doi.org/10.1186/s13223-018-0314-1
Bjermer, Leif, et al. "The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 15 (2019): 24. doi: https://doi.org/10.1186/s13223-018-0314-1
Bjermer L, Westman M, Holmström M, Wickman MC. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy Asthma Clin Immunol. 2019 Apr 16;15:24. doi: 10.1186/s13223-018-0314-1. eCollection 2019. PMID: 31015846; PMCID: PMC6469109.
Copy Download .nbib Format: NLM
[Intranasal azelastine in the treatment of perennial allergic rhinitis in children].

Jornal de pediatria

Oliveira CA, Braga CR, Solé D, Naspitz CK.
PMID: 14688906
J Pediatr (Rio J). 1996 Nov-Dec;72(6):394-9. doi: 10.2223/jped.650.

Twenty-five patients (5-15 years old) with perennial allergic rhinitis (PAR) for at least one year were treated with intranasal azelastine. The study was conducted in two separate occasions. In the first study, in a special prepared room, the patients...

Cite
Oliveira CA, Braga CR, Solé D, et al. Azelastina intranasal no tratamento da rinite alérgica perene em crianças. [Intranasal azelastine in the treatment of perennial allergic rhinitis in children]. J Pediatr (Rio J). 1996;72(6):394-9doi: 10.2223/jped.650.
Oliveira, C. A., Braga, C. R., Solé, D., & Naspitz, C. K. (1996). Azelastina intranasal no tratamento da rinite alérgica perene em crianças. [Intranasal azelastine in the treatment of perennial allergic rhinitis in children]. Jornal de pediatria, 72(6), 394-9. https://doi.org/10.2223/jped.650
Oliveira, C A, et al. "Azelastina intranasal no tratamento da rinite alérgica perene em crianças." [Intranasal azelastine in the treatment of perennial allergic rhinitis in children]. Jornal de pediatria vol. 72,6 (1996): 394-9. doi: https://doi.org/10.2223/jped.650
Oliveira CA, Braga CR, Solé D, Naspitz CK. Azelastina intranasal no tratamento da rinite alérgica perene em crianças. [Intranasal azelastine in the treatment of perennial allergic rhinitis in children]. J Pediatr (Rio J). 1996 Nov-Dec;72(6):394-9. doi: 10.2223/jped.650. Portuguese. PMID: 14688906.
Copy Download .nbib Format: NLM
MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis.

Journal of asthma and allergy

van Weissenbruch R, Klimek L, Gálffy G, Emmeluth M, Koltun A, Kopietz F, Nguyen DT, Kuhl HC, Pohl W, Scadding GK, Price D, Mullol J.
PMID: 33293835
J Asthma Allergy. 2020 Dec 02;13:633-645. doi: 10.2147/JAA.S277734. eCollection 2020.

PURPOSE: Patients with poorly controlled allergic rhinitis (AR) experience nasal symptoms, sleep disturbances, activity impairment, and decreased quality-of-life (QoL). MP-AzeFlu is safe and effective for moderate-to-severe seasonal and perennial AR, but its impact on QoL requires investigation in the...

Cite
van Weissenbruch R, Klimek L, Gálffy G, et al. MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis. J Asthma Allergy. 2020;13:633-645doi: 10.2147/JAA.S277734.
van Weissenbruch, R., Klimek, L., Gálffy, G., Emmeluth, M., Koltun, A., Kopietz, F., Nguyen, D. T., Kuhl, H. C., Pohl, W., Scadding, G. K., Price, D., & Mullol, J. (2020). MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis. Journal of asthma and allergy, 13633-645. https://doi.org/10.2147/JAA.S277734
van Weissenbruch, Ranny, et al. "MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis." Journal of asthma and allergy vol. 13 (2020): 633-645. doi: https://doi.org/10.2147/JAA.S277734
van Weissenbruch R, Klimek L, Gálffy G, Emmeluth M, Koltun A, Kopietz F, Nguyen DT, Kuhl HC, Pohl W, Scadding GK, Price D, Mullol J. MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis. J Asthma Allergy. 2020 Dec 02;13:633-645. doi: 10.2147/JAA.S277734. eCollection 2020. PMID: 33293835; PMCID: PMC7719305.
Copy Download .nbib Format: NLM
A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score.

Allergy & rhinology (Providence, R.I.)

Sardana N, Santos C, Lehman E, Craig T.
PMID: 28569235
Allergy Rhinol (Providence). 2010 Apr 01;1(2):13. doi: 10.2500/aap.2010.31.3308.

Rhinitis symptom complex consists of rhinorrhea, congestion, itchy mucosa, itchy eyes, and sneezing. Available medications vary in their benefit for each of these symptoms. It was the purpose of this article to compare symptom reduction with three different classes...

Cite
Sardana N, Santos C, Lehman E, et al. A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score. Allergy Rhinol (Providence). 2010;1(2):13doi: 10.2500/aap.2010.31.3308.
Sardana, N., Santos, C., Lehman, E., & Craig, T. (2010). A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score. Allergy & rhinology (Providence, R.I.), 1(2), 13. https://doi.org/10.2500/aap.2010.31.3308
Sardana, Niti, et al. "A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score." Allergy & rhinology (Providence, R.I.) vol. 1,2 (2010): 13. doi: https://doi.org/10.2500/aap.2010.31.3308
Sardana N, Santos C, Lehman E, Craig T. A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score. Allergy Rhinol (Providence). 2010 Apr 01;1(2):13. doi: 10.2500/aap.2010.31.3308. PMID: 28569235.
Copy Download .nbib Format: NLM
Virtual screening using the ligand ZINC database for novel lipoxygenase-3 inhibitors.

Bioinformation

Monika, Kour J, Singh K.
PMID: 23888100
Bioinformation. 2013 Jun 29;9(11):583-7. doi: 10.6026/97320630009583. Print 2013.

The leukotrienes constitute a group of arachidonic acid-derived compounds with biologic activities suggesting important roles in inflammation and immediate hypersensitivity. Epidermis-type lipoxygenase-3 (ALOXE3), a distinct subclass within the multigene family of mammalian lipoxygenases, is a novel isoenzyme involved in...

Cite
Monika, Kour J, Singh K. Virtual screening using the ligand ZINC database for novel lipoxygenase-3 inhibitors. Bioinformation. 2013;9(11):583-7doi: 10.6026/97320630009583.
Monika, Kour, J., & Singh, K. (2013). Virtual screening using the ligand ZINC database for novel lipoxygenase-3 inhibitors. Bioinformation, 9(11), 583-7. https://doi.org/10.6026/97320630009583
Monika, et al. "Virtual screening using the ligand ZINC database for novel lipoxygenase-3 inhibitors." Bioinformation vol. 9,11 (2013): 583-7. doi: https://doi.org/10.6026/97320630009583
Monika, Kour J, Singh K. Virtual screening using the ligand ZINC database for novel lipoxygenase-3 inhibitors. Bioinformation. 2013 Jun 29;9(11):583-7. doi: 10.6026/97320630009583. Print 2013. PMID: 23888100; PMCID: PMC3717187.
Copy Download .nbib Format: NLM
Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis.

Journal of natural science, biology, and medicine

Hazarika AK, Singh PK.
PMID: 26604594
J Nat Sci Biol Med. 2015 Aug;6:S10-2. doi: 10.4103/0976-9668.166051.

BACKGROUND: Allergic conjunctivitis is commonly observed eye diseases in Sikkim, India due to the abundance of seasonal pollens, environmental pollutants, and house dust. We evaluated the efficacy of topical 0.03% tacrolimus eye ointment in the management of simple allergic...

Cite
Hazarika AK, Singh PK. Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. J Nat Sci Biol Med. 2015;6:S10-2doi: 10.4103/0976-9668.166051.
Hazarika, A. K., & Singh, P. K. (2015). Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. Journal of natural science, biology, and medicine, 6S10-2. https://doi.org/10.4103/0976-9668.166051
Hazarika, Ajit Kumar, and Singh, Prodip Kumar. "Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis." Journal of natural science, biology, and medicine vol. 6 (2015): S10-2. doi: https://doi.org/10.4103/0976-9668.166051
Hazarika AK, Singh PK. Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. J Nat Sci Biol Med. 2015 Aug;6:S10-2. doi: 10.4103/0976-9668.166051. PMID: 26604594; PMCID: PMC4630738.
Copy Download .nbib Format: NLM
In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains.

Journal of global antimicrobial resistance

Boyd NK, Lee GC, Teng C, Frei CR.
PMID: 34560306
J Glob Antimicrob Resist. 2021 Sep 21;27:167-171. doi: 10.1016/j.jgar.2021.09.003. Epub 2021 Sep 21.

OBJECTIVES: We hypothesised that one or more of the non-antibiotic candidates selected for this study would demonstrate antibiotic activity against Staphylococcus aureus.METHODS: We determined minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) for non-antibiotic drugs (amlodipine, azelastine, ebselen...

Cite
Boyd NK, Lee GC, Teng C, et al. In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains. J Glob Antimicrob Resist. 2021;27:167-171doi: 10.1016/j.jgar.2021.09.003.
Boyd, N. K., Lee, G. C., Teng, C., & Frei, C. R. (2021). In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains. Journal of global antimicrobial resistance, 27167-171. https://doi.org/10.1016/j.jgar.2021.09.003
Boyd, Natalie K, et al. "In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains." Journal of global antimicrobial resistance vol. 27 (2021): 167-171. doi: https://doi.org/10.1016/j.jgar.2021.09.003
Boyd NK, Lee GC, Teng C, Frei CR. In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains. J Glob Antimicrob Resist. 2021 Sep 21;27:167-171. doi: 10.1016/j.jgar.2021.09.003. Epub 2021 Sep 21. PMID: 34560306.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 59 entries